Business · 22/04/2014Updated: 10/17/2026 · 1 min read
Eli Lilly and Company, et al.; FDA Withdraws Approval of 3 New Drug Applications and 41 Abbreviated New Drug Applications
Summary
The US Food and Drug Administration (FDA) has withdrawn approval of 3 new drug applications and 41 abbreviated new drug applications (ANDAs) from multiple pharmaceutical companies, following written notifications from the applicants that the drug products are no longer commercially available.
Original source language: Federal Register — Food and Drug AdministrationOpen original release →